title: [Our experience in using fluorescence in situ hybridization FISH-Uro Vysion in diagnostics of urothelial carcinoma].
abstract: Urothelial carcinoma is a disease at high risk of recurrence after the initial therapy (70-80%) and with the tendency to progression accomplishing the recurrence (30%). Long lasting monitoring of patients with urothelial carcinoma is necessary. Cystoscopy and cytology are currently the primary modalities used to detect and monitor urothelial carcinoma. However, cytology has relatively poor sensitivity especially in well differentiated tumors. Cystoscopy is an invasive and relatively expensive method. Therefore, methods improving detection of urothelial carcinoma from urine specimens are employed. Uro Vysion (Vysis) fluorescence in situ hybridization (FISH) for improved detection of urothelial carcinoma was evaluated.
  
  
  METHODS
  Bladder tumor progression is accompanied by increased chromosomal instability and aneuploidy of chromosomes 3, 7, 17 and loss of locus 9p21. A total of 124 patients were analyzed at Dpts. of Urology and Pathology, Faculty Hospital in Brno. Cytologically analyzed urine specimens were tested by FISH and simultaneously cystoscopy was employed including biopsy for histological examination.
  
  
  RESULTS
  FISH analysis was positive in 35 cases, including 5 cases with negative biopsy and cytology. Negative FISH result was detected in 24 cases where the malignant status was determined. The sensitivity of FISH in our series was 58.9% and the specificity 88.1%.
  
  
  CONCLUSIONS
  FISH is a relatively simple, speedy and non invasive diagnostic method. It detects the symptoms of malignity on the molecular level, which leads to earlier diagnosis and therapy and, hence, to potential extended survival. FISH makes it possible to take decision in cases of atypical or unclear cytological finding. The FISH method using the Uro Vysion kit appears as a prospective non invasive method capable of early UK detection, with a higher sensitivity than the standard cytology of urine.
authors.affiliation: Urologická klinika FN a LF MU, Brno. v-vit@email.cz
authors.forename: V
authors.initials: V
authors.lastname: Vit
authors.forename: D
authors.initials: D
authors.lastname: Pacík
authors.forename: A
authors.initials: A
authors.lastname: Cermák
authors.forename: I
authors.initials: I
authors.lastname: Falková
authors.forename: J
authors.initials: J
authors.lastname: Smardová
authors.forename: R
authors.initials: R
authors.lastname: Hrabálková
authors.forename: M
authors.initials: M
authors.lastname: Svitáková
authors.forename: Z
authors.initials: Z
authors.lastname: Pavlovský
authors.forename: M
authors.initials: M
authors.lastname: Votava
mesh_terms: D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis*